The global pharmaceutical industry is undergoing considerable change as i) patents on branded products expire opening the
door to generic equivalents, ii) lifestyle drugs become more socially acceptable and iii) scientific advances enhance
innovative drug research and development. These factors have combined to create significant opportunities for burgeoning
generic and biotech companies. These structural changes have also driven big pharmaceutical companies to outsource processes
as a means to quicken their development cycle and reduce costs. As providers of outsourced clinical trials and laboratory
analysis, CRO's will continue to benefit from these positive industry trends.
Established in 1992 as a contract research organization (CRO) Algorithme quickly developed a strong reputation within the
global CRO industry as a top tier service provider and preferred employer in the Montreal area. With a solid management team
in place and a formidable base of business, growth through acquisition became a top priority at the company as a means to
capitalize on the robust industry fundamentals and diversify their base of operations. To execute on this strategy, Algorithme
sought a partner with significant financial and operational expertise. |
